2seventy bio, Inc (TSVT): Price-to-Revenue Ratio

Symbol and logo of brand 2seventy Bio (TSVT)

Leadership in CAR-T therapy for myeloma via Abecma has defined the strategic direction for 2seventy bio, Inc. (TSVT). On the GURU.Markets platform, the market capitalization-to-revenue ratio visualizes these shifts, and the metric currently holds around 5.40. Revenues are based on royalties and partner payments, while the deliberate narrowing of the project portfolio to a single product is aimed at reaching operational break-even.

TSVT: 2seventy bio, Inc. P/S Multiple 07/04/2022 - 05/24/2025

Metric breakdowns and analytics for 2seventy Bio (TSVT)

- current price and projected stock value:
Price Chart 2seventybio.com|TSVT - Price Target Chart
- stock exchange capitalization data:
Market Value 2seventy Bio|TSVT - Real Price to Acquire Entire Company
- issuer book value statistics:
Accounting Value of a Share 2seventy bio|TSVT - Book Capitalization|Market Value to Equity Ratio 2seventybio.com|TSVT - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital 2seventy bio, Inc.|TSVT - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio 2seventy bio, Inc|TSVT - Company Aggregate Debts|Debts to Book Value 2seventy Bio|TSVT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 2seventy bio|Intermediate Liquidity Ratio 2seventybio.com
- earnings and valuation multiples information:
TSVT - Net Profit|Expected Net Income 2seventy bio, Inc.|TSVT - P/E Multiple|Projected Price to Earnings Ratio 2seventy bio Inc.|TSVT - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation 2seventy Bio|TSVT - Operating profit EBITDA|Net earnings per share (EPS TTM) 2seventy bio|TSVT - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months 2seventybio.com|TSVT - Net earnings per share growth this year|Expected net earnings per share growth next year 2seventy bio, Inc.
- issuer revenue and sales details:
TSVT - Company Revenue|Company Projected Revenue 2seventybio.com|TSVT - Price-to-Revenue Coefficient|Forward P/S Multiple 2seventy Bio
General company analysis:TSVT - 2seventybio.com
Mass-produced product of 2seventybio.com

The P/S ratio compares the market value of a business to its annual revenue, allowing for an assessment of the premium investors are willing to pay per unit of revenue. For 2seventy bio, Inc. (TSVT), which commercializes the CAR-T therapy Abecma, current P/S dynamics reflect market expectations for the scaling of genetic engineering, where a sharp increase in the indicator may signal a revaluation of future successes in treating myeloma.

Who 2seventy bio, Inc. competes with

Price-to-Revenue Ratio LEGN (legendbiotech.com)|Price-to-Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Revenue Ratio|ALLO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RNAC (Selecta Biosciences Inc.)|CLLS: P/S Multiple|Price-to-Revenue Multiple cariboubio.com CRBU|TIL (Instil Bio) - P/S Multiple|Price to Sales Genenta GNTA|Price-to-Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple SNTI (Senti Biosciences)|Adaptimmune Therapeutics plc (ADAP) - Price to Sales|CERO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Market Cap to Revenue|CRGX: Market Cap to Sales Volume|PSTX (Poseida Therapeutics) - P/S Multiple|GRCL: Market Capitalization-to-Revenue Ratio